Exelixis has seen its share price climb over multiple time frames, so the real issue for anyone looking at the stock now is ...

Exelixis (EXEL) is drawing attention after a year of strong share performance. The stock is up about 51% over the past 12 ...

Exelixis offers strong growth potential, trading at 14x 2026E EPS, below sector median, with robust oncology franchises and disciplined R&D spending. Cabozantinib remains the near-term growth driver, ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Featuring daily updates of ...

Exelixis relies heavily on cabozantinib, with potential growth from its NETs approval, but faces patent expiration (after 2030). Zanzalintinib shows promise in ongoing trials but lacks definitive data ...

Investors in Exelixis Inc (Symbol: EXEL) saw new options become available this week, for the August 2025 expiration. One of the key data points that goes into the price an option buyer is willing to ...

・The FDA will now decide on Exelixis’s new application by March 3, 2027. ・A March decision would push a possible U.S. launch out of this year and into 2027. ・William Blair said it was “surprised” by ...

Shares of Exelixis, Inc. EXEL gained 7.4% on June 23, after the company announced positive top-line results from the late-stage STELLAR-303 study. This phase III study is a global, multicenter, ...